Lexicon Details Presentations Relating to LX9211 for Treatment of Diabetic Peripheral Neuropathic Pain

 Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development

Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stage Phase 3 studies

Presentations are as follows:

• NeuPSIG 2023 International Congress on Neuropathic Pain, Sept. 7-9; Lisbon, Portugal; Poster Presentation
• 33^rd Annual Meeting of the Diabetic Neuropathy Study Group (NeuroDiab), Sept. 28-Oct. 1; Thessaloniki, Greece; Oral Presentation
• 59^th Annual Meeting of the European Association for the Study of Diabetes (EASD), Oct. 2-6; Hamburg, Germany and online; Oral Presentation
• 17^th Annual Pain Therapeutics Summit (Arrowhead Conference), Oct. 19-20; San Diego, California; Oral Presentation
• 2^nd World Brain Disorders and Neuroscience Summit (BDNS), Nov. 9-11; Singapore and online; Oral Presentation

https://www.biospace.com/article/releases/lexicon-announces-series-of-presentations-relating-to-lx9211-its-investigational-drug-for-the-treatment-of-diabetic-peripheral-neuropathic-pain-dpnp-/